专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010118384A2 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS 审中-公开
标题翻译：用于雌激素缺乏型乳腺的AMYLIN激动剂化合物
公开(公告)号：WO2010118384A2
公开(公告)日：2010-10-14
申请号：PCT/US2010/030625
申请日：2010-04-09
申请人： AMYLIN PHARMACEUTICALS, INC. , ROTH, Jonathan, D. , TREVASKIS, James, L. , PARKES, David, G.
发明人： ROTH, Jonathan, D. , TREVASKIS, James, L. , PARKES, David, G.
IPC分类号： A61K38/26
CPC分类号： A61K38/22 , A61K38/2264 , A61K38/23 , C07K14/575 , A61K2300/00
摘要： Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
摘要翻译：本文提供了通过施用胰岛淀粉样多肽激动剂化合物治疗哺乳动物雌激素缺乏症的方法。本文还提供了在雌激素缺乏的哺乳动物中治疗肥胖和超重的方法; 在雌激素缺乏的哺乳动物中减少或维持体重和/或体内脂肪的方法; 以及通过施用有效量的胰淀素激动剂化合物来增加哺乳动物中Bdnf水平的方法。雌激素缺乏可能是由更年期，绝经前期，绝经后，卵巢功能障碍，过度切除术，子宫切除术等引起的。胰淀素激动剂化合物可以是本领域已知的或本文所述的任何一种，例如普兰林肽，达维兰苷或SEQ ID NO：142。

2. 发明申请

WO2011063414A1 POLYPEPTIDE CONJUGATE 审中-公开
标题翻译：多聚糖
公开(公告)号：WO2011063414A1
公开(公告)日：2011-05-26
申请号：PCT/US2010/057890
申请日：2010-11-23
申请人： AMYLIN PHARMACEUTICALS, INC. , FOROOD, Behrouz, Bruce , GHOSH, Soumitra, S. , TREVASKIS, James, L. , SUN, Chengzao
发明人： FOROOD, Behrouz, Bruce , GHOSH, Soumitra, S. , TREVASKIS, James, L. , SUN, Chengzao
IPC分类号： A61K38/00 , A61P3/04
CPC分类号： C07K14/605 , A61K38/00 , A61K47/54 , A61K47/542 , A61K47/554 , A61K47/60 , A61K47/64 , A61K47/643 , C07K14/575 , C07K14/57563 , C07K14/585
摘要： The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.
摘要翻译：本公开提供多肽缀合物具有多种改善的药理学和药代动力学性质及其在治疗各种疾病和病症如糖尿病和/或肥胖症中的用途。

3. 发明申请

WO2010118384A8 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS 审中-公开
标题翻译：用于雌激素缺乏型乳腺的AMYLIN激动剂化合物
公开(公告)号：WO2010118384A8
公开(公告)日：2011-05-05
申请号：PCT/US2010030625
申请日：2010-04-09
申请人： AMYLIN PHARMACEUTICALS INC , ROTH JONATHAN D , TREVASKIS JAMES L , PARKES DAVID G
发明人： ROTH JONATHAN D , TREVASKIS JAMES L , PARKES DAVID G
IPC分类号： A61K38/00 , A61K38/28
CPC分类号： A61K38/22 , A61K38/2264 , A61K38/23 , C07K14/575 , A61K2300/00
摘要： Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
摘要翻译：本文提供了通过施用胰岛淀粉样多肽激动剂化合物治疗哺乳动物雌激素缺乏症的方法。本文还提供了在雌激素缺乏的哺乳动物中治疗肥胖和超重的方法; 减少或维持雌激素缺乏型哺乳动物体重和/或体重脂肪的方法; 以及通过施用有效量的胰淀素激动剂化合物来增加哺乳动物中Bdnf水平的方法。雌激素缺乏可能是由更年期，围绝经期，绝经后，卵巢功能障碍，过度切除术，子宫切除术等引起的。胰淀素激动剂化合物可以是本领域已知的或本文所述的任何一种，例如普兰林肽，达维兰苷或SEQ ID NO：142。

4. 发明申请

WO2010118384A3 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS 审中-公开
标题翻译：用于雌激素缺乏型哺乳动物的AMYLIN激动剂化合物
公开(公告)号：WO2010118384A3
公开(公告)日：2011-01-27
申请号：PCT/US2010030625
申请日：2010-04-09
申请人： AMYLIN PHARMACEUTICALS INC , ROTH JONATHAN D , TREVASKIS JAMES L , PARKES DAVID G
发明人： ROTH JONATHAN D , TREVASKIS JAMES L , PARKES DAVID G
IPC分类号： A61K38/26 , A61K38/28
CPC分类号： A61K38/22 , A61K38/2264 , A61K38/23 , C07K14/575 , A61K2300/00
摘要： Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
摘要翻译：本文提供了通过施用胰淀素激动剂化合物来治疗哺乳动物雌激素不足的方法。本文还提供了治疗雌激素缺乏型哺乳动物肥胖和超重的方法; 在雌激素缺乏的哺乳动物中减少或维持体重和/或体脂肪的方法; 以及通过施用有效量的胰岛淀粉样多肽激动剂化合物来增加哺乳动物Bdnf水平的方法。雌激素缺乏症可能是由绝经，围绝经期，绝经后，卵巢功能障碍，全乳切除术，子宫切除术等引起的。胰淀素激动剂化合物可以是本领域已知的或本文描述的任何化合物，例如普兰林肽，达瓦林肽或SEQ ID NO：142。

5. 发明申请

WO2007019426A3 A NOVEL PEPTIDE INVOLVED IN ENERGY HOMEOSTASIS 审中-公开
标题翻译：参与能源管理的新型肽
公开(公告)号：WO2007019426A3
公开(公告)日：2009-04-23
申请号：PCT/US2006030686
申请日：2006-08-07
申请人： UNIV LOUISIANA STATE , BUTLER ANDREW A , TREVASKIS JAMES L
发明人： BUTLER ANDREW A , TREVASKIS JAMES L
IPC分类号： A61K38/17 , C07K14/435 , C07K16/18 , C12N1/13 , C12N5/10 , C12N15/01 , C12N15/12 , C12N15/63
CPC分类号： C07K14/47 , A61K38/1709 , A61K38/22 , A61K38/2264 , C07K14/4702 , C07K16/18 , G01N33/68
摘要： The expression of a mRNA encoding a putative 76 amino acid, secreted protein ("Swirl") was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Swirl mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Swirl by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Swirl protein. The expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by SWIRl adenoviral treatment in Lepob/Lepob mice. Full-length SWIRl peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.
摘要翻译：发现编码推定的76个氨基酸的分泌蛋白（“Swirl”）的mRNA的表达与空腹甘油三酯和胆固醇水平呈负相关。使用重组腺病毒增加两种小鼠模型的肥胖，KK-Ay和Lepob / Lepob小鼠中Swirl mRNA的表达。通过腺病毒注射可以显着地和可重复地过度表达Swirl，从而降低了两种模型中的空腹甘油三酯和胆固醇水平。此外，制备过表达Swirl蛋白的转基因小鼠品系。在Lepob / Lepob小鼠中通过SWIR1腺病毒处理降低了参与脂肪生成（脂肪酸合酶）和FAS蛋白水平的关键基因的表达。通过口服摄入，注射，皮下贴片或鼻内途径递送的全长SWIR1肽或其衍生物，同系物，类似物或模拟物可用作高胆固醇血症，高甘油三酯血症，胰岛素抵抗，肥胖症，糖尿病和/或能量失衡。

6. 发明申请

WO2007019426A2 A NOVEL PEPTIDE INVOLVED IN ENERGY HOMEOSTASIS 审中-公开
标题翻译：参与能源管理的新型肽
公开(公告)号：WO2007019426A2
公开(公告)日：2007-02-15
申请号：PCT/US2006/030686
申请日：2006-08-07
申请人： BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE , BUTLER, Andrew, A. , TREVASKIS, James, L.
发明人： BUTLER, Andrew, A. , TREVASKIS, James, L.
IPC分类号： A61K38/17 , C07K14/705
CPC分类号： C07K14/47 , A61K38/1709 , A61K38/22 , A61K38/2264 , C07K14/4702 , C07K16/18 , G01N33/68
摘要： The expression of a mRNA encoding a putative 76 amino acid, secreted protein ("Swirl") was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Swirl mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Swirl by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Swirl protein. The expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by SWIRl adenoviral treatment in Lepob/Lepob mice. Full-length SWIRl peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.
摘要翻译：发现编码推定的76个氨基酸的分泌蛋白（“Swirl”）的mRNA的表达与空腹甘油三酯和胆固醇水平呈负相关。使用重组腺病毒增加两种小鼠模型的肥胖，KK-Ay和Lepob / Lepob小鼠中Swirl mRNA的表达。通过腺病毒注射可以显着地和可重复地过度表达Swirl，从而降低了两种模型中的空腹甘油三酯和胆固醇水平。此外，制备过表达Swirl蛋白的转基因小鼠品系。在Lepob / Lepob小鼠中通过SWIR1腺病毒处理降低了参与脂肪生成（脂肪酸合酶）和FAS蛋白水平的关键基因的表达。通过口服摄入，注射，皮下贴片或鼻内途径递送的全长SWIR1肽或其衍生物，同系物，类似物或模拟物可用作高胆固醇血症，高甘油三酯血症，胰岛素抵抗，肥胖症，糖尿病和/或能量失衡。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式